A new study published in JAMA Psychiatry on March 29, 2023, shows that the wider availability of opioid use disorder (OUD)–related telehealth services and medications during the COVID-19 pandemic led to a reduced likelihood of fatal drug overdoses among Medicare beneficiaries.

New CDC data reveal that U.S. tuberculosis (TB) cases totaled 8,300 last year, an increase of 5%. CDC is urging communities at greater risk and health care providers to “Think. Test. Treat TB.”

A new study in JAMA Pediatrics published March 20, 2023, suggests that pulse oximetry overestimated arterial oxygen saturation in Black children.

An FDA advisory panel backed the use of Pfizer’s nirmatrelvir/ritonavir antiviral (Paxlovid) as a treatment for adults with COVID-19 who are at high risk for severe illness. The endorsement is expected to allow the drug, which is available under an EUA, to receive full FDA approval.

A new study published in NEJM found that bempedoic acid (Nexletol—Esperion Therapeutics) modestly reduced the risk of heart attacks, strokes, and other complications from heart disease. However, it did not reduce the overall mortality rate. Bempedoic acid was approved by FDA 3 years ago to reduce low-density lipoprotein (LDL) levels.